Cost-effectiveness analysis of afatinib vs gefitinib in EGFR-Mutated population with advanced non-small-cell lung cancer

被引：0
作者：
Chouaid, Christos
De Pouvourville, Gerard
Laura, Luciani
机构：
来源：
EUROPEAN RESPIRATORY JOURNAL | 2017年 / 50卷
关键词：
D O I：
10.1183/1393003.congress-2017.PA2794
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA2794
引用
收藏
页数：1
相关论文
共 50 条
[41]   Case sharing of a patient re-challenged with afatinib for EGFR-mutated advanced non-small cell lung cancer [J].
Lee, Victor H. F. .
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 :4-6
[42]   Afatinib in advanced non-small-cell lung cancer [J].
Di Maio, Massimo ;
Gridelli, Cesare ;
Grossi, Francesco ;
Novello, Silvia ;
de Marinis, Filippo .
LUNG CANCER MANAGEMENT, 2013, 2 (06) :493-504
[43]   Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer [J].
Leighl, Natasha B. ;
Karaseva, Nina ;
Nakagawa, Kazuhiko ;
Cho, Byoung-Chul ;
Gray, Jhanelle E. ;
Hovey, Tina ;
Walding, Andrew ;
Ryden, Anna ;
Novello, Silvia .
EUROPEAN JOURNAL OF CANCER, 2020, 125 :49-57
[44]   Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non-small-cell lung cancer patients: a prospective observational study [J].
Peng, Duanyang ;
Liang, Pingan ;
Zhong, Congying ;
Xu, Peng ;
He, Yanqing ;
Luo, Yuxi ;
Wang, Xia ;
Liu, Anwen ;
Zeng, Zhimin .
BMC CANCER, 2022, 22 (01)
[45]   A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer [J].
Yu, Wanjun ;
Ye, Fei ;
Yuan, Xiao ;
Ma, Yali ;
Mao, Chaoming ;
Li, Xiaoqin ;
Li, Jian ;
Dai, Chunhua ;
Qian, Fenhong ;
Li, Junrong ;
Fan, Xiujuan ;
Zhou, Yuepeng ;
Wang, Deqiang ;
Guo, Zhenhong ;
An, Huazhang ;
Zhang, Minghui ;
Chen, Deyu ;
Xia, Sheng .
BMC CANCER, 2021, 21 (01)
[46]   A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer [J].
Wanjun Yu ;
Fei Ye ;
Xiao Yuan ;
Yali Ma ;
Chaoming Mao ;
Xiaoqin Li ;
Jian Li ;
Chunhua Dai ;
Fenhong Qian ;
Junrong Li ;
Xiujuan Fan ;
Yuepeng Zhou ;
Deqiang Wang ;
Zhenhong Guo ;
Huazhang An ;
Minghui Zhang ;
Deyu Chen ;
Sheng Xia .
BMC Cancer, 21
[47]   Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population [J].
Noorwati SUTANDYO ;
Arif HANAFI ;
Mulawarman JAYUSMAN .
中国肺癌杂志, 2019, (09) :562-567
[48]   cost-effectiveness of aumolertinib as first-line treatment for EGFR-mutated advanced nonsmall-cell lung cancer [J].
Zhang, Huahua ;
Zheng, Xiaochun ;
Zhang, Yandong ;
Wang, Jiangfeng .
FUTURE ONCOLOGY, 2024, :2661-2670
[49]   Cost-effectiveness of lazertinib as first-line treatment in patients with EGFR-mutated advanced lung cancer [J].
Ku, Li-Jung Elizabeth ;
Tsai, Jui-Hung ;
Chen, Li-Jun ;
Yang, Szu-Chun .
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
[50]   Cost-effectiveness of tyrosine kinase inhibition in first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer. [J].
Han, Jiaqi ;
Hu, Huabin ;
Liao, Mengting ;
She, Longjiang ;
Yao, Linli ;
Ding, Dong ;
Zeng, Shan ;
Shen Liang-Fang ;
Huang, Jin .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345